The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

GH May 2024 17.500 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

2.2500

0.0000

(0.00%)

As of 03:31PM EDT. Market open.

Zacks
Curious about Guardant Health (GH) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Guardant Health (GH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Zacks
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Business Wire
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
PALO ALTO, Calif., April 22, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration Medical Devices Advisory Committee is scheduled to review the premarket approval (PMA) application for the company’s Shield™ blood test for colorectal cancer (CRC) screening on Thursday, May 23, 2024.